Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 19

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 19
---
. •“Libra” refers to Libra Sciences Limited, a VIE in which we hold 97.27% economic interest and 31.51% voting power. Libra is incorporated under the laws of the Cayman Islands. We are not deemed as the primary beneficiary of Libra for accounting purposes. •“LIMS” refers to Laboratory Information Management System. •“Major Patent Jurisdictions” refers to the United States, member states of the European Patent Organization and the People’s Republic of China. •“MCI” refers to Mild Cognitive Impairment. •“microRNA” (miRNA) refers to non -codingsmall nucleic acid molecules. •“Nativus” refers to Nativus Life Sciences Limited, a wholly -ownedsubsidiary of Aptorum Group. •“NMPA” refers to China’s National Medical Products Administration and its predecessor, the China Food and Drug Administration. •“ND” refers to neurodegenerative diseases. •“NDA” refers to a New Drug Application issued by the FDA. •“NIH” refers to National Institute of Health. •“PD” refers to Parkinson’s disease. •“PRC” and “China” refer to the People’s Republic of China. •“Restructure” refers to the Company’s change from an investment fund with management shares and non -votingparticipating redeemable preference shares to a holding company with operating subsidiaries, effective as of March1, 2017. •“R&D” refers to research and development. •“R&D Center” refers to an in -housepharmaceutical development center located in Hong Kong Science and Technology Park. •“Risk Stratification” in the context of clinical tests refers to the process of categorizing individuals or patients into different risk groups based on certain factors or parameters measured through diagnostic tests. The goal is to identify individuals who are at higher risk of developing a particular condition or experiencing certain outcomes, such as disease progression based on their testing results. Risk stratification typically involves assessing various clinical variables, biomarkers, demographic information, medical history, and other relevant factors to determine an individual’s level of risk for a certain condition. This information helps healthcare professionals tailor their management strategies, interventions, and follow -upplans according to the specific needs of each risk group. For example, in brain health, risk stratification may involve assessing factors such as miRNA profile, protein biomarker status, APOE genotype, and family history of AD to